Profile data is unavailable for this security.
About the company
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
- Revenue in EUR (TTM)276.59m
- Net income in EUR-12.17m
- Incorporated1988
- Employees426.00
- LocationPharming Group NVDarwinweg 24LEIDEN 2333 CRNetherlandsNLD
- Phone+31 715247400
- Fax+31 715247445
- Websitehttps://www.pharming.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai New World Co Ltd | 132.43m | 7.35m | 583.94m | 1.14k | 79.42 | 1.15 | -- | 4.41 | 0.0947 | 0.0947 | 1.71 | 6.53 | 0.1952 | 3.98 | 9.70 | 966,843.40 | 1.06 | 0.6394 | 1.42 | 0.8838 | 39.62 | 36.38 | 5.45 | 3.58 | 1.54 | -- | 0.1156 | 71.59 | -1.21 | -7.49 | 121.22 | 13.84 | -26.50 | 5.92 |
| Jinyao Pharmaceutical Co Ltd | 376.60m | 16.02m | 592.44m | 2.88k | 36.91 | 1.58 | -- | 1.57 | 0.1225 | 0.1225 | 2.87 | 2.86 | 0.5229 | 2.54 | 7.50 | 1,087,823.00 | 3.52 | 1.87 | 5.78 | 3.31 | 43.18 | 45.67 | 6.73 | 3.30 | 1.15 | 14.34 | 0.1685 | 65.00 | -15.00 | -0.6786 | 14.01 | -3.78 | -23.40 | 19.63 |
| Zevra Therapeutics Inc | 35.00m | -79.33m | 596.97m | 59.00 | -- | 16.87 | -- | 17.06 | -1.90 | -1.90 | 0.823 | 0.7503 | 0.2506 | -- | 3.88 | 687,932.20 | -56.78 | -37.95 | -68.88 | -48.83 | 84.42 | -- | -226.64 | -193.51 | 2.93 | -10.59 | 0.5943 | -- | -14.02 | 12.96 | -129.13 | -- | 196.92 | -- |
| Shanghai Hile Bio-Technology Co Ltd | 31.51m | 22.30m | 598.96m | 366.00 | 23.71 | 3.16 | -- | 19.01 | 0.3209 | 0.3209 | 0.4122 | 2.41 | 0.1509 | 1.15 | 2.37 | 717,290.70 | 11.73 | 4.15 | 14.11 | 5.65 | 66.96 | 52.88 | 77.68 | 25.09 | 7.53 | -- | 0.0096 | 26.17 | 12.59 | -0.5053 | 172.28 | 69.73 | -26.47 | 67.20 |
| Pharming Group NV | 276.59m | -12.17m | 601.52m | 426.00 | -- | 3.24 | -- | 2.17 | -0.0186 | -0.0186 | 0.4329 | 0.2708 | 0.7592 | 0.6133 | 7.44 | 649,275.60 | -3.38 | 2.22 | -5.11 | 2.68 | 88.98 | 89.40 | -4.45 | 3.88 | 2.00 | 1.96 | 0.3563 | -- | 21.15 | 9.46 | -12.26 | -- | -49.98 | -- |
| Nika Pharmaceuticals Inc | 138.00 | -76.38k | 610.75m | -- | -- | -- | -- | 4,426,376.00 | -0.00008 | -0.00008 | 0.00 | -0.0002 | 0.0042 | -- | -- | -- | -231.68 | -21,428.06 | -- | -- | -- | -- | -55,356.25 | -- | -- | -- | 7.69 | -- | -- | -- | -47.74 | -- | -- | -- |
| Eyepoint Pharmaceuticals Inc | 48.33m | -126.58m | 611.21m | 165.00 | -- | 2.38 | -- | 12.65 | -2.41 | -2.41 | 0.9262 | 4.34 | 0.162 | 1.18 | 32.42 | 339,648.50 | -42.43 | -35.88 | -49.96 | -42.05 | 93.29 | 84.82 | -261.91 | -201.78 | 7.79 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Shanghai MicuRx Pharmaceutical Co Ltd | 15.66m | -48.04m | 616.22m | 188.00 | -- | 13.36 | -- | 39.34 | -0.6072 | -0.6072 | 0.1983 | 0.5862 | 0.1334 | 0.5142 | 4.31 | 694,008.50 | -40.91 | -31.40 | -50.80 | -35.41 | 82.86 | 82.42 | -306.74 | -503.67 | 2.90 | -- | 0.4822 | -- | 43.51 | -- | -4.65 | -- | 51.72 | -- |
| Sinotherapeutics Inc | 61.12m | 15.04m | 617.66m | 312.00 | 41.07 | 3.94 | -- | 10.11 | 0.2764 | 0.2764 | 1.12 | 2.88 | 0.3608 | 2.78 | 6.42 | 1,631,842.00 | 8.88 | 10.22 | 9.54 | 11.26 | 49.89 | 65.76 | 24.61 | 31.88 | 8.72 | -- | 0.00001 | 13.77 | 70.61 | 29.80 | 109.09 | 94.07 | 32.01 | -- |
Data as of Jul 18 2025. Currency figures normalised to Pharming Group NV's reporting currency: Euro EUR
7.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DWS Investment GmbHas of 04 Jul 2025 | 17.28m | 2.54% |
| BlackRock Fund Advisorsas of 07 Jul 2025 | 9.84m | 1.45% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 6.74m | 0.99% |
| Dimensional Fund Advisors LPas of 04 Jul 2025 | 5.92m | 0.87% |
| FundLogic SASUas of 14 Jan 2025 | 2.79m | 0.41% |
| KBC Asset Management NVas of 31 Dec 2024 | 2.10m | 0.31% |
| BlackRock Advisors (UK) Ltd.as of 07 Jul 2025 | 1.40m | 0.21% |
| DWS Investments (UK) Ltd.as of 03 Jul 2025 | 1.20m | 0.18% |
| Soci�t� G�n�rale Gestion SAas of 21 May 2025 | 1.17m | 0.17% |
| SSgA Funds Management, Inc.as of 02 Jul 2025 | 1.03m | 0.15% |
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
